News & Topics
Antibody Delivery Technology Empowers Immunotherapy against Glioblastoma and Suppresses Side Effects
The Innovation Center of NanoMedicine, Kawasaki Institute of Industrial Promotion, in collaboration with the Department of Bioengineering, Graduate School of Engineering, The University of Tokyo, has succeeded in efficiently delivering an immune checkpoint inhibitor (ICI) into the mouse brain, confirming its high efficacy and specificality in treating orthotopically transplanted mice with glioblastoma (GBM).
The contents of this research were published in Nature Biomedical Engineering (IF = 25.671).
At the press seminar held online on Wednesday, October 6, Dr. Kazunori Kataoka, Director General, Innovation Center of NanoMedicine, Dr. Tao Yang, Research Scientist, Kataoka/Kinoh Lab., Innovation Center of NanoMedicine, Dr. Yuki MOCHIDA, Senior Research Scientist, Kataoka/Kinoh Lab., Innovation Center of NanoMedicine took the rostrum, and there were the deep, enthusiastic and passionate discussions with journalists in science section, the general paper and biotech journals.
【Kazunori Kataoka, Director General, iCONM】
【Tao Yang, Research Scientist, iCONM】
【Yuki MOCHIDA, Senior Research Scientist, iCONM】